SES’ 2Q26 results showed improving commercialization momentum despite lower sequential revenue, with all four product lines contributing and gross margin expanding to 22.6%. The strongest read-through came from drones, where NDAA-compliant capacity is scaling toward 1M cells annually while demand from several large prospects already exceeds near-term deliverable capacity. ESS also gained an important U.S. catalyst through Sol-Ark certification, while Molecular Universe and materials continue to build early commercial traction. FY26 guidance was reaffirmed, though the $30M–$35M revenue target still requires a sizable 2H ramp supported by ESS, drones, and materials.